Group 1 - The article highlights the upcoming deadline of December 15, 2025, for investors to file a lead plaintiff motion in a case related to MoonLake Immunotherapeutics (NASDAQ: MLTX) [1] - The class period for the case is defined as between March 10, 2024, and September 29, 2025, during which investors purchased common stock of MoonLake [1] - Investors who suffered losses in MoonLake Immunotherapeutics are encouraged to contact the Law Offices of Howard G. Smith for assistance [1]

Core Viewpoint - A class action securities lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud affecting investors between March 10, 2024, and September 29, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding MoonLake's drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique Nanobody structure does not provide superior clinical benefits [2]. - Allegations include that SLK's supposed increased tissue penetration does not translate to clinical efficacy, and thus the defendants lacked a reasonable basis for their positive claims about SLK's superiority over monoclonal antibodies [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of MoonLake Immunotherapeutics during the specified Class Period of the upcoming lead plaintiff deadline on December 15, 2025 [1]. Group 1: Class Action Details - Investors who bought MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lawsuit claims that the defendants made false or misleading statements regarding the efficacy of their product compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. for securities fraud, related to safety issues with its Novum IQ Large Volume Pump, which has led to significant stock price decline and investor losses [1][5][6]. Summary by Sections Lawsuit Announcement - The Law Offices of Frank R. Cruz are encouraging Baxter shareholders to inquire about a class action lawsuit filed on behalf of investors who purchased Baxter common stock between February 23, 2022, and July 30, 2025 [1][2]. Safety Issues - On April 7, 2025, a Missouri news outlet reported serious safety concerns regarding Baxter's Novum IQ Large Volume Pump, citing a whistleblower who claimed the pumps were unsafe for patient treatment [3]. - Following this, Baxter issued warning letters about potential underinfusion risks, later revealing 79 reports of serious injuries and two patient deaths associated with the device [4]. Stock Price Impact - On July 31, 2025, Baxter announced a voluntary pause on shipments and installations of the Novum LVP, resulting in a stock price drop of $6.24, or 22.4%, closing at $21.61 per share [5]. Allegations in the Lawsuit - The lawsuit alleges that Baxter made materially false and misleading statements and failed to disclose critical information about the Novum LVP's systemic defects, which posed risks of serious injury or death to patients [6][7]. - Specific allegations include the company's knowledge of device malfunctions, inadequate remedial measures, and misleading positive statements about its business prospects [7].

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics (MLTX) for securities fraud, following disappointing Phase 3 results for its drug candidate sonelokimab (SLK) [1][3]. Summary by Sections Lawsuit Announcement - The Law Offices of Frank R. Cruz announced a class action lawsuit on behalf of shareholders who purchased MLTX common stock between March 10, 2024, and September 29, 2025, with a deadline of December 15, 2025, for filing a lead plaintiff motion [1]. Disappointing Drug Results - On September 28, 2025, MoonLake announced that SLK failed to match the efficacy of its competitor's drug, BIMZELX, despite prior claims of its superiority [3]. - The company had promoted SLK's nanobody structure as superior but allegedly did not disclose that it targeted the same molecules as BIMZELX and lacked proven advantages [3]. Stock Price Impact - Following the announcement of the disappointing results, MoonLake's stock plummeted by $55.74, or 89.9%, closing at $6.24 per share on September 29, 2025, significantly harming investors [4]. Allegations in the Lawsuit - The lawsuit alleges that during the Class Period, the defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects, including: 1. SLK and BIMZELX share the same molecular targets [5]. 2. SLK's nanobody structure would not provide superior clinical benefits over BIMZELX [5]. 3. The supposed increased tissue penetration of SLK would not translate to clinical efficacy [5]. 4. Positive statements about the company's business were materially misleading and lacked a reasonable basis [5].

Core Points - A class action lawsuit has been filed against Baxter International, Inc. for alleged securities fraud and unlawful business practices [2] - Baxter announced a voluntary and temporary pause in shipments and installations of its Novum LVP medical device, impacting its stock price significantly [2] Company Overview - Baxter International, Inc. is involved in the medical device sector, specifically focusing on intravenous fluid delivery systems [2] - The company has offered an alternative product, the Spectrum infusion pump, to customers affected by the pause in Novum LVP shipments [2] Financial Impact - Following the announcement of the shipment pause, Baxter's stock price dropped by $6.29 per share, representing a 22.4% decline, closing at $21.76 per share on July 31, 2025 [2]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against MoonLake (NASDAQ: MLTX) due to allegations of violations of federal securities laws related to misleading statements about its product SLK compared to BIMZELX [1][3]. Group 1: Allegations Against MoonLake - The complaint alleges that MoonLake and its executives made false and misleading statements regarding the efficacy and clinical benefits of SLK compared to traditional monoclonal antibodies [3]. - Specific claims include that SLK and BIMZELX share the same molecular targets, and that SLK's unique structure does not provide superior clinical benefits or efficacy [3]. - Following the announcement of Phase 3 VELA program results, which showed SLK's failure to demonstrate competitive efficacy, MoonLake's stock price dropped by $55.75 per share, or 89.9%, closing at $6.24 [4]. Group 2: Legal Proceedings and Investor Actions - Investors who purchased MoonLake securities between March 10, 2024, and September 29, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1]. - The deadline for seeking the role of lead plaintiff in the federal securities class action against MoonLake is December 15, 2025 [1]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [5].

Core Points - Tronox Holdings plc is facing a class action securities lawsuit due to alleged securities fraud that occurred between February 12, 2025, and July 30, 2025 [1] - The lawsuit claims that Tronox provided misleading statements about its commercial division's performance while failing to accurately forecast demand for its products, leading to a significant decline in sales and a lowered financial outlook [2] - Following the announcement of poor financial results for Q2 2025, Tronox's stock price dropped approximately 38% in one day, from $5.14 to $3.19 per share [2] Company Performance - Tronox's Q2 2025 financial results revealed a significant reduction in TiO2 sales, attributed to a weaker coatings season and increased competition [2] - The company revised its full-year revenue guidance downward and cut its dividend by 60% as a result of the sales decline [2] Legal Proceedings - Investors who suffered losses during the specified period have until November 3, 2025, to request to be appointed as lead plaintiff in the class action [3] - Participation in the lawsuit does not require any out-of-pocket costs for class members [3] Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]

Core Viewpoint - A class action securities lawsuit has been filed against Semler Scientific, Inc. for alleged securities fraud affecting investors between March 10, 2021, and April 15, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit claims that Semler Scientific failed to disclose a significant investigation by the U.S. Department of Justice regarding violations of the False Claims Act, while discussing potential violations in hypothetical terms [3]. - Defendants' public statements are alleged to have been materially false and misleading throughout the relevant period [3]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until October 28, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the U.S. [5].

Core Viewpoint - A class action securities lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected investors between March 10, 2024, and September 29, 2025 [1][2]. Group 1: Lawsuit Details - The complaint claims that the defendants made false statements regarding the company's drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique Nanobody structure does not provide superior clinical benefits [2]. - It is alleged that the supposed increased tissue penetration of SLK does not translate to clinical efficacy, indicating a lack of reasonable basis for the positive statements made about SLK's superiority over traditional monoclonal antibodies [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, emphasizing that there is no cost or obligation to participate [3]. Group 3: Legal Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].